INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO

Inmune Bio

30/10/2025 20:30

Overview

INmune Bio Q3 net loss narrows to $6.5 mln from $12.1 mln year-over-year

Operating expenses for Q3 decreased to $7.4 mln from $12.3 mln year-over-year

Company announces leadership changes with David Moss as new CEO

Outlook

Company plans to file CORDStrom™ MAA submission mid-2026

Company expects End of Phase 2 meeting for XPro™ in Q1 2026

Final data on INKmune CARE-PC trial expected in Q4 2026

Result Drivers

CORDStrom MANUFACTURING - Successful completion of first two commercial pilot-scale manufacturing runs in preparation for regulatory filings

INKmune TRIAL PROGRESS - CARE-PC trial met primary endpoint and two secondary endpoints, indicating NK cell proliferation and function

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$6.47 mln
Q3 Basic EPS
-$0.24
Q3 Operating Expenses
$7.43 mln
Q3 Operating Income
-$7.43 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for INmune Bio Inc is $7.00, about 74% above its October 29 closing price of $1.82

Press Release: ID:nGNX6NVPqd

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)